Interventions and assessments
toxicity, death, tumor
DISEASE PROGRESSION, TUMOR
Patients received either 500 mg dostarlimab or 200 mg pembrolizumab, administered as a 30-minute intravenous (IV) infusion, every 3 weeks (Q3W) for up to 35 cycles (~24 months) or until disease progression, withdrawal of consent, unacceptable toxicity, or death. Patients also received pemetrexed (500 mg/mDuring treatment, clinical assessments of tumor responses (per RECIST v1.1, by BICR and by the Investigator; treatment decisions were based on investigator assessment) were supported by serial imaging (computed tomography or magnetic resonance imaging) carried out on Weeks 6 and 12, then every 9 weeks up to Week 48, and every 12 weeks thereafter until discontinuation of study treatment. Other regions (e.g., brain) were imaged at baseline, as clinically indicated, by computed tomography or magnetic resonance imaging.Safety (monitoring of AEs) was assessed throughout the treatment period and at visits occurring 30 and 90 days after the last dose of study treatment. Post-treatment follow-up assessments occurred 180 days after the last dose of study treatment and every 90 days thereafter until death, withdrawal of consent, or end of study.